My watch list
my.chemeurope.com  
Login  

Gliclazide



Gliclazide
Systematic (IUPAC) name
3-(7-azabicyclo[3.3.0]oct-7-yl)-
1-(4-methylphenyl)sulfonyl-urea
Identifiers
CAS number 21187-98-4
ATC code A10BB09
PubChem 3475
DrugBank APRD00460
Chemical data
Formula C15H21N3O3S 
Mol. mass 323.412 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®. DIAMICRON MR is also distributed as: Diabeton MR, Diamicron 30mg, Diamicron LM 30mg, Diamicron MR 30 mg, Diamicron Uno 30mg, Dianormax MR, Diaprel MR and Uni Diamicron.

Additional recommended knowledge

Contents

Form and Composition:

Each tablet contains 80 mg of gliclazide.

Not marketed in the United States.

Indication:

Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.

Dosage:

40 to 240 mg depending on response, once or twice daily before food, no more that 160 mg at a time.

Properties:

Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. Glycemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.

Contraindications:

type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.

Interactions:

Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, β-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, β-blockers, possibly ACE inhibitors.

Adverse effects:

Hypoglycemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).

Overdosage:

Possible severe hypoglycemia requiring urgent IV glucose and monitoring.

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Gliclazide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE